Zapping liver cancer: electric pulses target tumors, spare healthy tissue
NCT ID NCT07192731
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a procedure called irreversible electroporation (IRE), which uses short electrical pulses to kill liver cancer cells while leaving nearby healthy tissue unharmed. It is for people with early-stage liver cancer (HCC) who have good liver function. The goal is to see if IRE can completely destroy tumors after 6 months, offering a less invasive alternative to surgery or heat-based ablation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Irreversible electroporation (IRE) device (Nanoknife)
- What this could lead to
- If successful, this could offer a targeted, non-surgical option to destroy liver tumors while sparing healthy tissue, potentially controlling liver cancer without major side effects.
- What could go wrong
- This is an early-stage, small study (50 people) with no comparison group, so results may not apply widely. The procedure carries risks like bleeding or infection, and it may not fully eradicate tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Manchester Royal Infirmiary
Manchester, M13 9WL, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Exercise as medicine: tailored workouts may rebuild strength after cancer
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test